Moderna Inc. has announced positive results from a Phase 3 efficacy study of its seasonal influenza vaccine candidate, mRNA-1010. The study, which compared mRNA-1010 to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older, demonstrated a superior relative vaccine efficacy of 26.6% in the overall study population. The vaccine candidate showed strong efficacy against various influenza strains, including A/H1N1, A/H3N2, and the B/Victoria lineages. Safety and tolerability were consistent with previous studies, with most adverse reactions being mild and no significant differences observed in the rates of adverse events between groups. Moderna plans to present these findings at an upcoming medical conference and will engage with regulators on filing submissions for mRNA-1010.